• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy?

    Simply Wall St·04/04/2026 00:28:07
    Listen to the news
    • Summit Therapeutics Inc. recently presented data for its investigational bispecific antibody ivonescimab at the 2026 European Lung Cancer Congress in Copenhagen, highlighting progress in multiple Phase III trials across non-small cell lung cancer and colorectal cancer.
    • The company now has 15 announced, ongoing, or completed Phase III studies for ivonescimab, including four Summit-sponsored global trials and ten China-based trials run by partner Akeso Inc., underscoring how extensively this single asset is being evaluated across tumor types and geographies.
    • We’ll now examine how ivonescimab’s expanding Phase III footprint, including the new HARMONi-GI3 colorectal program, could influence Summit’s investment narrative.

    This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

    Summit Therapeutics Investment Narrative Recap

    To own Summit today, you have to believe ivonescimab can convert its broad late stage footprint into approvals and future cash flows, despite no current revenue and sizeable losses. The ELCC 2026 data presentation reinforces that ivonescimab is being tested at scale, but it does not materially change the near term focus on the U.S. FDA review of the HARMONi BLA or the key risk that overall survival data might fall short of regulatory expectations.

    The most relevant recent announcement is the FDA’s acceptance of Summit’s BLA for ivonescimab plus chemotherapy in EGFR mutated NSCLC, with a potential action date of November 14, 2026. When you set that against the expanding Phase III program, including the newer HARMONi-GI3 colorectal trial, it highlights how much of Summit’s future hinges on one drug clearing both regulatory and commercial hurdles in large, highly competitive oncology markets.

    Yet while the pipeline breadth is encouraging, investors should also be aware that...

    Read the full narrative on Summit Therapeutics (it's free!)

    Summit Therapeutics' narrative projects $848.4 million revenue and $125.2 million earnings by 2029. This implies an earnings increase of about $1.2 billion from -$1.1 billion today.

    Uncover how Summit Therapeutics' forecasts yield a $29.18 fair value, a 51% upside to its current price.

    Exploring Other Perspectives

    SMMT 1-Year Stock Price Chart
    SMMT 1-Year Stock Price Chart

    Some of the most optimistic analysts were, even before this ELCC update, modeling about US$3.1 billion of revenue and US$1.7 billion of earnings by 2029, so this new data could either reinforce or challenge that brighter view compared with more cautious takes on ivonescimab’s risks.

    Explore 6 other fair value estimates on Summit Therapeutics - why the stock might be worth less than half the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.